Cargando…

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib

PURPOSE: Tyrosine kinase inhibitors like sunitinib and sorafenib are commonly used to treat metastatic renal cell cancer patients. Cubilin is a membrane protein expressed in the proximal renal tubule. Cubilin and megalin function together as endocytic receptors mediating uptake of many proteins. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niinivirta, Marjut, Enblad, Gunilla, Edqvist, Per-Henrik, Pontén, Fredrik, Dragomir, Anca, Ullenhag, Gustav J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427164/ https://www.ncbi.nlm.nih.gov/pubmed/28260162 http://dx.doi.org/10.1007/s00432-017-2365-y

Ejemplares similares

Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Tumoral Pyruvate Kinase L/R as a Predictive Marker for the Treatment of Renal Cancer Patients with Sunitinib and Sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2019)

Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
por: Niinivirta, Marjut, et al.
Publicado: (2020)

A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma
por: Gremel, Gabriela, et al.
Publicado: (2017)

Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients
por: Aasebø, Kristine Ø., et al.
Publicado: (2019)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

Sorafenib and sunitinib: A dermatologist's perspective
por: Pragasam, Vijendran, et al.
Publicado: (2014)

Phylogenetic analysis of cubilin (CUBN) gene
por: Shaik, Abjal Pasha, et al.
Publicado: (2013)

Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer
por: Ma, Xin, et al.
Publicado: (2016)

Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
por: Schlemmer, Marcus, et al.
Publicado: (2019)

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
por: Lindskog, Magnus, et al.
Publicado: (2022)

Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma
por: Bourlon, Maria T., et al.
Publicado: (2016)

Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study
por: Ambring, Anneli, et al.
Publicado: (2012)

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
por: Randrup Hansen, Caroline, et al.
Publicado: (2017)

Amnionless-mediated glycosylation is crucial for cell surface targeting of cubilin in renal and intestinal cells
por: Udagawa, Tomohiro, et al.
Publicado: (2018)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial
por: Bazarbashi, Shouki, et al.
Publicado: (2023)

Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib
por: Fiorio Pla, Alessandra, et al.
Publicado: (2014)

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors
por: Fu, Yali, et al.
Publicado: (2018)

Cubilin expression is monoallelic and epigenetically augmented via PPARs
por: Aseem, Obaidullah, et al.
Publicado: (2013)

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
por: Coppin, Chris
Publicado: (2010)

Successful treatment with sorafenib for sunitinib‐refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib
por: Morinaga, Ryota, et al.
Publicado: (2018)

Proximal Tubular Expression Patterns of Megalin and Cubilin in Proteinuric Nephropathies
por: Sun, Jia, et al.
Publicado: (2017)

Bioinformatics for The Prognostic Value and Function of Cubilin (CUBN) in Colorectal Cancer
por: Wu, Yibin, et al.
Publicado: (2020)

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib
por: Di Fiore, F, et al.
Publicado: (2011)

Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study
por: Gu, Liangyou, et al.
Publicado: (2017)

Effects of sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular risk indices in renal cell carcinoma
por: Lai, Silvia, et al.
Publicado: (2020)

Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist
por: Gole, Prachi, et al.
Publicado: (2014)

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
por: Walraven, Maudy, et al.
Publicado: (2018)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis
por: Liu, Xiu-Lan, et al.
Publicado: (2020)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
por: Bæk Møller, Nanna, et al.
Publicado: (2019)

Isolated benign persistent proteinuria with novel association of CUBN (cubilin) variants
por: Shi, Vivian, et al.
Publicado: (2023)

Serum markers change for intraocular metastasis in renal cell carcinoma
por: Sun, Tie, et al.
Publicado: (2021)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
por: Juengel, Eva, et al.
Publicado: (2015)

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
por: Cai, Wen, et al.
Publicado: (2019)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses
por: Shu, Mao, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2k2iuki578hmkfl3jgij1t2uk0